Impaired Survival With LVEF <60 Percent in Aortic Stenosis

Share this content:
Impaired Survival With LVEF &#60;60 Percent in Aortic Stenosis
Impaired Survival With LVEF <60 Percent in Aortic Stenosis

THURSDAY, Jan. 4, 2018 (HealthDay News) -- For patients with severe aortic stenosis (AS), left ventricular ejection fraction (LVEF) below 60 percent is associated with impaired survival, according to a study published online Dec. 27 in JACC: Cardiovascular Interventions.

Tomohiko Taniguchi, M.D., from the Kyoto University Graduate School of Medicine in Japan, and colleagues examined the prognostic impact of LVEF in 3,794 patients with severe AS. The patients were categorized into four groups according to LVEF at index echocardiography: <50 percent, 50 to 59 percent, 60 to 69 percent, and ≥70 percent (conservative strategy: 388, 390, 1,025, and 800 patients, respectively; initial aortic valve replacement (AVR) strategy: 206, 170, 375, and 440 patients, respectively).

The researchers found that the cumulative five-year incidence of the primary outcome measure (composite of aortic valve-related death or heart failure hospitalization) was significantly higher in patients with LVEF <50 percent and 50 to 59 percent compared to those with LVEF 60 to 69 percent and ≥70 percent in the conservative group; the negative effect of low LVEF was markedly attenuated in the initial AVR group. Compared with LVEF ≥70 percent, LVEF <50 percent and 50 to 59 percent, but not 60 to 69 percent, were independently associated with poorer outcomes in the conservative group, after adjustment for confounders.

"Survival in severe AS is impaired when LVEF is <60 percent, and these findings have implications for decision-making with regards to timing of surgical intervention," the authors write.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »